These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 30970371

  • 1. Amyloid β42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death.
    Ribbe M, Kern S, Börjesson Hansson A, Östling S, Zetterberg H, Blennow K, Skoog I.
    Dement Geriatr Cogn Disord; 2019; 47(1-2):114-124. PubMed ID: 30970371
    [Abstract] [Full Text] [Related]

  • 2. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Jul; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [Abstract] [Full Text] [Related]

  • 7. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.
    JAMA; 2009 Jul 22; 302(4):385-93. PubMed ID: 19622817
    [Abstract] [Full Text] [Related]

  • 8. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.
    J Alzheimers Dis; 2014 Jul 22; 41(2):377-86. PubMed ID: 24614902
    [Abstract] [Full Text] [Related]

  • 9. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.
    Almeida RP, Schultz SA, Austin BP, Boots EA, Dowling NM, Gleason CE, Bendlin BB, Sager MA, Hermann BP, Zetterberg H, Carlsson CM, Johnson SC, Asthana S, Okonkwo OC.
    JAMA Neurol; 2015 Jun 22; 72(6):699-706. PubMed ID: 25893879
    [Abstract] [Full Text] [Related]

  • 10. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D.
    J Neurol Neurosurg Psychiatry; 2011 Feb 22; 82(2):160-4. PubMed ID: 21047883
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
    Pan C, Korff A, Galasko D, Ginghina C, Peskind E, Li G, Quinn J, Montine TJ, Cain K, Shi M, Zhang J.
    J Alzheimers Dis; 2015 Feb 22; 45(3):709-19. PubMed ID: 25613100
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.
    J Alzheimers Dis; 2016 Feb 22; 51(4):1069-83. PubMed ID: 26923009
    [Abstract] [Full Text] [Related]

  • 13. Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study.
    Johansson L, Kern S, Zetterberg H, Blennow K, Börjesson-Hansson A, Rosengren L, Guo X, Skoog I.
    Dement Geriatr Cogn Disord; 2018 Feb 22; 46(1-2):90-99. PubMed ID: 30145588
    [Abstract] [Full Text] [Related]

  • 14. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
    Wallin AK, Blennow K, Andreasen N, Minthon L.
    Dement Geriatr Cogn Disord; 2006 Feb 22; 21(3):131-8. PubMed ID: 16391474
    [Abstract] [Full Text] [Related]

  • 15. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.
    Lancet Neurol; 2006 Mar 22; 5(3):228-34. PubMed ID: 16488378
    [Abstract] [Full Text] [Related]

  • 16. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ.
    J Alzheimers Dis; 2017 Mar 22; 60(3):1119-1128. PubMed ID: 28984585
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.
    Arch Neurol; 2009 Mar 22; 66(3):382-9. PubMed ID: 19273758
    [Abstract] [Full Text] [Related]

  • 18. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
    Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM.
    Neurology; 2012 Jan 03; 78(1):47-54. PubMed ID: 22170879
    [Abstract] [Full Text] [Related]

  • 19. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.
    Tapiola T, Pirttilä T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, Soininen H.
    Neurosci Lett; 2000 Feb 18; 280(2):119-22. PubMed ID: 10686392
    [Abstract] [Full Text] [Related]

  • 20. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J, Hanseeuw BJ, Hatling FB, Judge KA, Schultz AP, Chhatwal JP, Blacker D, Sperling RA, Johnson KA, Hyman BT, Gómez-Isla T.
    J Alzheimers Dis; 2017 Feb 18; 60(4):1451-1459. PubMed ID: 29036824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.